Where the Mouth meets the Model. Creating lasting value for your R&D with the motto: De-risk early. Secure your Formulation. Advance to Clinic with confidence.
WHAT MAKES OUR COMPANY UNIQUE
We provide the first-in-class humanized oral mucosa platform to de-risk your R&D pipeline from formulation to clinic.
WHAT WE DO
Offer oral mucosa toxicity screening, ML-powered predictive safety and efficacy analysis and intuitive formulation guidance for Oral Care Products, Dental Devices, Pharma, Biotech & Nutraceutical Industries, within the scope of New Approach Methodologies (NAMs) with a focus on oral mucosa & disease modeling.
OUR MISSION
To partner with leading organizations across Asia-Pacific and eventually beyond in transforming preclinical R&D into AI-powered, customer-centric, NAM-based workflows that de-risk early, secure an intuitive formulation guidance workflow and advance to clinic with confidence.
FOLLOW THE 2 STEPS BELOW TO DE-RISK + ACCELERATE YOUR R&D:
STEP 1: Choose our R&D AI-powered oral tissue platform from our catalog below
STEP 2: Fill out this Request Form with ALL your information & hit SUBMIT
AFTER STEP 2: In about 48h, we will send you more details as well as the catalog and will set up a technical call with you.
Organ-on-chips/MPS
Our R&D partners can work with several MPS combining tissue models with host-pathogen interactions. Context of Use (CoU): Xerostomia/Dry Mouth, Dry-eye Disease, Oral Mucositis. Target tissues: Oral mucosa, Salivary Glands
Organoids & 3D Tissue Equivalents
Readily bioassembled with magnetic bioprinting or tissue-mimetic in-house manufactured hydrogels. Target/CoU: Oral Mucosa, Oral dryness/mucositis, Salivary Glands
Project Consultation for in vitro/in silico Predictive Analytics (ML/AI) & Customized Preclinical Models
2D, Spheroids & Tumoroids
Promptly manufactured overnight by various in-house 3D platforms at our Bioprinting Center. Target: any type of oral and craniofacial cells including cancer/immortalized cells
PLEASE HELP US FILL OUT THIS SURVEY TO ACCELERATE CURRENT MARKET R&D FOR ORAL HEALTH CARE PRODUCTS:
Preferred partners from industry-leading companies:
The NamsTek team is ready to accelerate your R&D
Product Manager
Dr. Jaggaiah (Jay) Gorantla | PhD Biochemistry
Liaison | MPS & Toxicology
Dr. Toan (Tuan) Phan | DDS, MSc PhD in Oral Biology
Liaison | Organoids, Spheroids, Assembloids
Dr. Yeo-Jun Yoon | PhD in Cell, Developmental & Cancer Biology
CEO & CTO
João (Joe) Ferreira | DDS MSc PhD in Oral Biology, Entrepreneurship in Life Sciences
Consultant | NAMS
Dr. Michael Phelan | MSc, PhD in Bioengineering | Founder & Principal Consultant at InnovApproach Consulting | Previous roles: Associate Director MPA Quality and Manufacturing for Integral Molecular | NIH predoc fellow | Doc specialist and app QC at Tekni-Plex, Inc.
Liaison | In-Silico Modeling & Predictive Toxicology
Dr. Chayada (Sandy) Piantham | DVM PhD in Bioinformatics & Computation
Senior Consultant | In vitro 3D Culture & Bioprinting
Dr. Glauco Souza | MBA, PhD in Physical Chemistry and Nanotechnology | Member of Board of Directors of SLAS and several companies and start-ups (Greiner Bio-One International, ChemoSen3D, Nano3D Biosciences)
Consultant | Bioengineering & Pharma
Dr. Pedro Baptista | PharmD, PhD in Biomedicine | Board Member of European Society for Artificial Organs (ESAO); Internal Scientific Advisory Board of IIS Aragon and iLITE French Consortium; Entrepreneur leading IIS Aragon spin-off company.
© NamsTek Limited. All rights reserved. Last update: 15.05.2026
HQ address: Unit B, 11/F, 23 Thomson Road, Wan Chai, Hong Kong SAR | Satellite Branches: Korea, Thailand, Vietnam